United States· US:71332-006_af2c2115-cb7d-4679-935a-c2200487b965
Gavreto
A pralsetinib product containing pralsetinib, registered in United States by Rigel Pharmaceuticals, Inc.. The same ATC class is registered in 8 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Pralsetinib is registered in 8 of 19 countries.
Countries holding a registration under ATC L01EX23 (pralsetinib), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 6 of them publish a price we can compare per daily dose
Pralsetinib · ATC L01EX23
8 / 19 countries
- Belgiumprice
- Denmark
- Finlandprice
- Franceprice
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- PRALSETINIB
- Manufacturer
- Rigel Pharmaceuticals, Inc.
- Country
- United States (US)
- ATC code
- L01EX23
- ATC class
- Pralsetinib
- Defined daily dose
- 0.4 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 6
- ndc117133200612120 CAPSULE in 1 BOTTLE (71332-006-12)
- ndc11713320066060 CAPSULE in 1 BOTTLE (71332-006-60)
- ndc11713320069090 CAPSULE in 1 BOTTLE (71332-006-90)
- ndc1171332-006-12
- ndc1171332-006-60
- ndc1171332-006-90
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
93 interactions on record for pralsetinib.
Graded by severity as the source publishes them — 16 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pralsetinib · interactions on record
93 records
- 16 severe
- 77 moderate
Most severe, free to view
- KetoconazoleH02CA03severe
- ClarithromycinJ01FA09severe
- KetoconazoleJ02AB02severe
- Darunavir and cobicistatJ05AR14severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pralsetinib in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumGavreto 100 mgBlueprint Medicines (Netherlands)
- SpainGAVRETO 100 MG CAPSULAS DURASBlueprint Medicines (Netherlands) B.V.
- FinlandGavretoBlueprint Medicines Netherlands B.V.
- FranceGAVRETO 100 mg, géluleBLUEPRINT MEDICINES (PAYS-BAS))
- United KingdomGavreto 100mg capsulesBlueprint Medicines (UK) Ltd
- NorwayGavretoRoche
- PolandGavretoRoche Registration GmbH
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8af0595f-7d73-415f-8223-228696f98457 GET /v1/drugs/8af0595f-7d73-415f-8223-228696f98457?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "100",
"substance": "PRALSETINIB",
"productndc": "71332-006",
"dosage_form": "CAPSULE",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA213721",
"marketing_category": "NDA"
}See everything about pralsetinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.